Case Letters

Subcutaneous *Saksenaea vasiformis* infection presenting as disfiguring facial plaques

Sir,

A 51-year-old Thai labourer presented with painless masses on the forehead, around both eyes and nose for 2 months. Four months earlier, he had a shallow abrasion on the forehead after an accident. Some weeks later, an infiltrative mass gradually developed. Despite the treatment with antibiotics and serial wound debridement, the mass slowly enlarged. He was afebrile and had no systemic symptoms. He was otherwise healthy with no underlying disease.

Physical examination revealed painless, firm, infiltrative plaques in centrofacial area involving the forehead, upper and lower eyelids as well as the nose [Figure 1a]. There was a limitation of bilateral upward gaze. Nasal cavity and nasopharyngeal mucosa were normal. Serology for HIV infection was negative.

Skin biopsy specimen was taken from the forehead. Hematoxylin and eosin stain revealed diffuse granuloma formations composed of multinucleated giant cells and lymphohistiocytes in the reticular dermis and subcutaneous tissue [Figure 2a]. Periodic acid-Schiff and Gomori’s methenamine silver stain revealed broad, non-septate hyphae with right angle branching [Figure 2b and c].

To identify the fungus, tissue culture was carried out on Sabouraud dextrose agar and white cottony growth was

---

**Figure 1a:** Diffuse erythematous infiltration with skin thickening over the forehead, both eyelids and the nose, causing facial disfigurement

**Figure 1b:** Improvement in lesions after two months of therapy
revealed [Figure 2d]. Wet preparation showed broad, non-septate hyphae without sporulation. Culture with distilled water method to induce sporulation has been attempted without success. Nevertheless, molecular analysis using universal fungal primers: ITS1 (5'-TCCGTAGGTGAACCTGCGG-3') and ITS4 (5'-TCCGCTTAATTGATATGC-3') amplified the internal transcribed sequence region of ribosomal DNA as previously described and blasted with GenBank database showed 99.9% identity with *Saksenaea vasiformis* from the biopsied tissue.¹

Treatment with amphotericin B (1.2 mg/kg/day) and itraconazole (600 mg/day) was administered for 40 days. A total dose of 2800 mg of amphotericin B was given. His facial plaque markedly improved [Figure 1b]. He was discharged with itraconazole (600 mg/day) as home medication but unfortunately was lost to follow-up.

*Saksenaea vasiformis* is a *Mucorales* member that can be found ubiquitously in soil from tropical and subtropical area. Since its first report as a human pathogen in 1977,¹ there are approximately only 45 cases reported till date.⁵ Seventy to eighty percent of the infection occurs in immunocompetent individuals with a history of trauma. Twenty percent of the patients are immunocompromised with an underlying condition such as diabetes mellitus, hematologic or solid organ malignancy. Unlike other mucormycosis, 73.8% of the infection is usually limited to soft tissue. However, less frequent rhino-orbito-cerebral, renal and disseminated infections have been reported.⁶

Cutaneous and subcutaneous infections caused by *Saksenaea vasiformis* primarily present with cellulitis, necrotizing fasciitis,
Letters to the Editor

abscess, papules and nodules that lead to ulceration as the pathogen is angioinvasive and triggers tissue necrosis. Only some cases present with subcutaneous masses without ulceration or mycetoma-like lesions. Interestingly, our patient presents with diffuse infiltration with skin thickening at the centrofacial area, causing severe disfigurement. This finding is distinctive for a rare cutaneous fungal infection, rhinofacial entomophthoromyces due to *Conidiobolus coronatus*. We were unable to find any previous report of *Saksenaea vasiformis* causing this specific lesion. Hence, our case highlights overlapping clinical features among zygomycosis.

Treatments of *Saksenaea vasiformis* infections include surgical procedures and/or systemic antifungal therapy, e.g., amphotericin B, liposomal amphotericin B and posaconazole. A recent *in vitro* study reported that itraconazole was active against *Saksenaea vasiformis* isolates. Therefore, itraconazole was included in our treatment regimen. Clinical improvement was observed; however, long-term outcome of the treatment cannot be evaluated since the patient was lost to follow-up.

In summary, we report this case of subcutaneous *Saksenaea vasiformis* infection mimicking rhinofacial entomophthoromyces. Clinical manifestations and histopathology are impossible to distinguish between the two types of zygomycosis. Definite diagnosis relies on fungus culture or molecular techniques to identify the causative organisms.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient has given his consent for his images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Acknowledgment

We would like to express our gratitude to Drs. Ratchathorn Panchaprateep and Jade Witisuwannakul, for their excellence care for the patient and Ms. Navaporn Worasilchai, for the molecular identification.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1. Chowdhary A, Randhawa HS, Gaur SN, Agarwal K, Kathuria S, Roy P, *et al.* *Schizopyllum commune* as an emerging fungal pathogen: A review and report of two cases. Mycoses 2013;56:1-10.
2. Gonzalez CE, Rinaldi MG, Sugar AM. Zygomycosis. Infect Dis Clin North Am 2002;16:895-914, vi.
3. Chayakulkeeree M, Ghanoun MA, Perfect JR. Zygomycosis: The re-emerging fungal infection. Eur J Clin Microbiol Infect Dis 2006;25:215-29.
4. Alvarez E, Garcia-Hermoso D, Sutton DA, Cano JF, Stchigel AM, Hoinard D, *et al.* Molecular phylogeny and proposal of two new species of the emerging pathogenic fungus *Saksenaea*. J Clin Microbiol 2010;48:4410-6.
5. Ajello L, Dean DF, Irwin RS. The zygomycete *Saksenaea vasiformis* as a pathogen of humans with a critical review of the etiology of zygomycosis. Mycologia 1976;68:52-62.
6. Gomes MZ, Lewis RE, Kontoyiannis DP. Mucormycosis caused by unusual mucormycetes, *non-Rhizopus*, *Mucor*, and *Lichtheimia* species. Clin Microbiol Rev 2011;24:411-45.
7. Kaushik R, Chander J, Gupta S, Sharma R, Punia RS. Fatal primary cutaneous zygomycosis caused by *Saksenaea vasiformis*: Case report and review of literature. Surg Infect (Larchmt) 2012;13:125-9.
8. Lye GR, Wood G, Nimmo G. Subcutaneous zygomycosis due to *Saksenaea vasiformis*: Rapid isolate identification using a modified sporulation technique. Pathology 1996;28:364-5.
9. Padhye AA, Koshi G, Anandi V, Ponniah J, Sitaram V, Jacob M, *et al.* First case of subcutaneous zygomycosis caused by *Saksenaea vasiformis* in India. Diagn Microbiol Infect Dis 1988;9:69-77.
10. Choon SE, Kang J, Neafie RC, Ragsdale B, Klassen-Fischer M, Carlson JA. Conidiobolomycosis in a young Malaysian woman showing chronic localized fibrosing leukocytoclastic vasculitis: A case report and meta-analysis focusing on clinicopathologic and therapeutic correlations with outcome. Am J Dermatopathol 2012;34:511-22.
11. Vega W, Orellana M, Zaror L, Gené J, Guerro J. *Saksenaea vasiformis* infections: Case report and literature review. Mycopathologia 2006;162:289-94.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.